Idiopathic osteoporosis in men

Current Osteoporosis Reports

Volumn 11, Issue 4, 2013, Pages 286-298

  Gennari, Luigi ^a   Bilezikian, John P ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Columbia University ^*  (United States)

Author keywords

Diagnosis of osteoporosis in men; Idiopathic osteoporosis; Male osteoporosis; Pathogenesis of male osteoporosis; Treatment of osteoporosis in men

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CALCIUM; DENOSUMAB; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; STRONTIUM RANELATE; THYROID HORMONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGE; ARTICLE; BONE DENSITOMETRY; BONE STRENGTH; FRACTURE; GROWTH; HUMAN; IDIOPATHIC OSTEOPOROSIS; MALE; MIDDLE AGED; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; POPULATION RESEARCH; PREVALENCE; RISK ASSESSMENT; YOUNG ADULT;

AGED; BONE AND BONES; BONE DENSITY; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; SEX FACTORS;

EID: 84890084862     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-013-0164-1     Document Type: Article

References (135)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-33.
2. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-64.
3. Melton LJ. Epidemiology of fractures. Osteoporosis: Etiology, Diagnosis and Management, Second Edition, Riggs BL, Melton LJ (Eds). Lippincott-Raven Publishers, Philadelphia; 1995. pp. 225-247
4. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab. 1999;84:3431-4.
5. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin N Am. 2007;36:399-419.
6. Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2011;25:321-35.
7. Ebeling P. Osteoporosis in men. N Engl J Med. 2008;358:1474-82.
8. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-7.
9. Osteoporosis and men, leaflet from osteoporosis Australia, MJA. 1997;167:51-515.
10. Johnell O, Borgstrom F, Jonsson B, Kanis J. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int. 2007;18:333-3.
11. Schwartz AV, Kelsey JL, Maggi S, et al. International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on aging. Osteoporos Int. 1999;9:242-53.
12. Center JR, Bliuc D, Nguyen ND, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297:387-94.
13. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513-21.
14. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878-82.
15. Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152:380-90.
16. Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res. 2005;20:494-500.
17. Schurch MA, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996;11:1935-42.
18. Mackey DC, Lui LY, Cawthon PM, et al. Study of osteoporotic fractures (SOF) and osteoporotic fractures in men (MrOS) research groups. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007;298:2381-8.
19. • Amin S, Melton III LJ, Achenbach SJ, et al. A distal forearm fracture in childhood is associated with an increased risk for future fragility fractures in adult men, but not women. J Bone Miner Res. 2013. doi: 10.1002/jbmr.1914. This study demonstrated a link between distal forearm fractures in childhood and the future risk of fragility fractures in adult men.
20. Boonen S, Kaufman JM, Goemaere S, et al. The diagnosis and treatment of skeletal osteoporosis: defining, assessing and preventing skeletal fragility in men. Eur J Int Med. 2007;18:6-17.
21. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407-13.
22. Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. JAMA. 2001;285:785-95
23. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. Adults from NHANES III. J Bone Miner Res. 1997;12:1761-8.
24. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;34:195-202.
25. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841-50.
26. • Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95:3-10. Update about of recent developments in male osteoporosis, along with an analysis of key unresolved issues.
27. Riggs BL, Melton III LJ, Robb RA, et al. A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res. 2004;19:1945-54.
28. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23:205-14.
29. Kirmani S, Christen D, van Lenthe GH, et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res. 2009;24:1033-42.
30. Duan Y, Beck TJ, Wang X-F, Seeman E. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res. 2003;18:1766-74.
31. Wang XF, Duan Y, Beck T, Seeman ER. Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone. 2005;36:978-86.
32. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E. Bone fragility in men - where are we? Osteoporos Int. 2006;17:1577-83.
33. Gennari L, Brandi ML. Genetics of male osteoporosis. Calcif Tissue Int. 2001;69:200-4.
34. Cohen-Solal ME, Baudoin C, Omouri M, Kuntz D, De Vernejoul MC. Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res. 1998;13:1909-14.
35. Gennari L, Klein R, Ferrari S. The genetics of peak bone mass. In Osteoporosis in Men; Orwoll E, Bilezikian JP, Vanderschueren D, (Eds), 2nd Edition, Section 3. Skeletal Genetics, Academic Press. 2009.
36. Smith DM, Nance WE, Kang KW, Christian JC, Johnston Jr CC. Genetic factors in determining bone mass. J Clin Invest. 1973;52:2800-8.
37. Van Pottelbergh I, Goemaere S, Zmierczak H, De Bacquer D, Kaufman JM. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. J Bone Miner Res. 2003;18:303-11.
38. Van Meurs JB, Schuit SC, Weel AE, et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet. 2003;12:1745-54.
39. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab. 2003;88:3075-81.
40. Khosla S, Riggs BL, Atkinson EJ, et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. J Clin Endocrinol Metab. 2004;89:1808-16.
41. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab. 2004;89:2803-10.
42. Crabbe P, Balemans W, Willaert A, et al. Missense mutations in LRP5 are not a common cause of idiopathic osteoporosis in adult men. J Bone Miner Res. 2005;20:1951-9.
43. Ferrari SL, Deutsch S, Baudoin C, et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone. 2005;37:770-5.
44. Lorentzon M, Swanson C, Eriksson AL, Mellström D, Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J Bone Miner Res. 2006;21:332-9.
45. van Meurs JB, Trikalinos TA, Ralston SH, et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008;299:1277-90.
46. Heshmati HM, Khosla S. Idiopathic osteoporosis: a heterogeneous entity. Ann Med Interne (Paris). 1998;149(2):77-81.
47. Khosla S. Editorial: idiopathic osteoporosis - is the osteoblast to blame? J Clin Endocrinol Metab. 1997;82:2792-4.
48. Pernow Y, Granberg B, Saaf M, Weidenhielm L. Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int. 2006;78:90-7.
49. Ruiz-Gaspà S, Blanch-Rubió J, Ciria-Recasens M, et al. Reduced proliferation and osteocalcin expression in osteoblasts of male idiopathic osteoporosis. Calcif Tissue Int. 2010;86:220-6.
50. Ciria-Recasens M, Pérez-Edo L, Blanch-Rubió J, et al. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone. 2005;36:926-30.
51. Pernow Y, Hauge EM, Linder K, Dahl E, Sääf M. Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int. 2009;84:430-8.
52. Ostertag A, Cohen-Solal M, Audran M, et al. Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone. 2009;44:413-7.
53. Fratzl-Zelman N, Roschger P, Misof BM, et al. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover. Calcif Tissue Int. 2011;88:378-87.
54. Patsch JM, Kohler T, Berzlanovich A, et al. Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res. 2011;26:1584-92.
55. Ostertag A, Collet C, Chappard C, et al. A case-control study of fractures in men with idiopathic osteoporosis: fractures are associated with older age and low cortical bone density. Bone. 2013;52:48-55.
56. Lapauw B, Vandewalle S, Taes Y, et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013;168(4):615-20.
57. Khosla S, Melton III LJ, Achenbach SJ, Oberg AL, Riggs BL. Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J Clin Endocrinol Metab. 2006;91:885-91.
58. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab. 1991;73:1016-25.
59. Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab. 1997;11:289-309.
60. Harman SM, Metter JF, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-31.
61. Khosla S, Melton III LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young vs elderly men. J Clin Endocrinol Metab. 2001;86:3555-61.
62. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab. 2003;88:5327-33.
63. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336-44.
64. Khosla S, Melton III LJ, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87:1443-50.
65. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004;89(12):5898-907.
66. Gennari L, Khosla S, Bilezikian JP. Estrogen and fracture risk in men. J Bone Miner Res. 2008;23:1548-51.
67. Mellström D, Vandenput L, Mallmin H, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. 2008;23(10):1552-60.
68. Reed BY, Zerwekh JE, Sakhaee K, et al. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res. 1995;10(8):1218-24.
69. Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 1997;82(9):2799-805.
70. Kurland ES, Chan FK, Rosen CJ, Bilezikian JP. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 1998;83(7):2576-9.
71. Gillberg P, Johansson AG, Ljunghall S. Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosis. Calcif Tissue Int. 1999;64(3):209-13.
72. Pietschmann P, Kudlacek S, Grisar J, et al. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest. 2001;31(5):444-51.
73. Van Pottelbergh I, Goemaere S, Zmierczak H, Kaufman JM. Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab. 2004;89(10):4949-53.
74. Lapauw B, Taes Y, Goemaere S, et al. Anthropometric and skeletal phenotype in men with idiopathic osteoporosis and their sons is consistent with deficient estrogen action during maturation. J Clin Endocrinol Metab. 2009;94(11):4300-8.
75. Evans SF, Davie MW. Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fracture. Calcif Tissue Int. 2002;70(1):9-15.
76. Johansson AG, Eriksen EF, Lindh E, et al. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab. 1997;82(9):2795-8.
77. Braidman I, Baris C, Wood L, et al. Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone. 2000;26(5):423-7.
78. Eriksson AL, Lorentzon M, Vandenput L, et al. Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J Clin Endocrinol Metab. 2009;94(3):1033-41.
79. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, et al. An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab. 1998;83:2286-90.
80. Curtis JR, Ewing SK, Bauer DC, et al. Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab. 2012;97(6):1937-44.
81. Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res. 2010;25(3):545-53.
82. Leib ES, Lewiecki EM, Binkley N, Hamdy RS. International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. J Clin Densitom. 2004;7:1-6.
83. Watts NB et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-22.
84. Lewiecki EM et al. The official positions of the International Society for Clinical Densitometry: perceptions and commentary. J Clin Densitom. 2009;12(3):267-71.
85. Kanis JA et al. Diagnostic thresholds for osteoporosis in men. In: Orwoll ES, Bilezikian JP, Vanderschueren D, editors. Osteoporosis in Men. Boston: Elsevier/Academic Press; 2010. p. 605-12.
86. Szulc P, Kaufman JM, Orwoll ES. Osteoporosis in men. J Osteoporos. 2012;2012:675984.
87. Taes Y, Lapauw B, Griet V, et al. Prevalent fractures are related to cortical bone geometry in young healthy men at age of peak bone mass. J Bone Miner Res. 2010;25:1433-40.
88. Szulc P, Boutroy S, Vilayphiou N, et al. Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. J Bone Miner Res. 2011;26:1358-67.
89. Orwoll ES, Marshall LM, Nielson CM, et al. Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res. 2009;24:475-83.
90. Wang X, Sanyal A, Cawthon PM, et al. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012;27:808-16.
91. Szulc P. Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos. 2011;2011:704015.
92. Bauer DC, Garnero P, Harrison SL, et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res. 2009;24(12):2032-8.
93. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-46.
94. Tosteson AN, Melton III LJ, Dawson-Hughes B, et al. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-47.
95. Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int. 2010;21:863-71.
96. Fraser LA, Langsetmo L, Berger C, CaMos Research Group, et al. Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int. 2011;22:829-37.
97. Ettinger B, Ensrud KE, Blackwell T, et al. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2013;24:1185-93.
98. Kanis JA, Bianchi G, Bilezikian JP, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789-98.
99. • Kaufman JM, Reginster JY, Boonen S, et al. Treatment of osteoporosis in men. Bone. 2013;53:134-44. Updated overview about current treatment options for osteoporosis in men.
100. Gillberg P, Mallmin H, Petrén-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 2002;87:4900-6.
101. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-10.
102. Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int. 2003;73:133-9.
103. Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alendronic acid in male osteoporosis. Clin Drug Investig. 2004;24:333-41.
104. Boonen S, Lorenc RS, Wenderoth D, et al. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone. 2012;51:383-8.
105. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24:719-25.
106. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29:311-5.
107. Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.
108. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Int Med. 2005;165:743-1748.
109. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly I.V. Infusion of zoledronic acid 5 mg vs a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25:2239-50.
110. Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone. 2012;50:289-95.
111. Lyles KW, Colón-Emeric CS, Magaziner JS, HORIZON Recurrent Fracture Trial, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809.
112. Boonen S, Orwoll E, Magaziner J, HORIZON Recurrent Fracture Trial, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011;59:2084-90.
113. •• Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714-23. Report of a recent placebo-controlled trial specifically designed to determine a difference in fracture endpoints in men, demonstrating the efficacy of zoledronic acid.
114. Smith MR, Egerdie B, Hernández Toriz N, Denosumab HALT Prostate Cancer Study Group, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
115. Orwoll E, Teglbjærg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-9.
116. Anderson FH, Francis RM, Peaston RT, Wastel HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 month's treatment on markers of bone formation and resorption. J Bone Miner Res. 1997;12(3):472-8.
117. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91(6):2011-6.
118. Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16(11):2118-25.
119. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res. 2004;19(9):1518-24.
120. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841-6.
121. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1Suppl):S45-50.
122. Slovik DM, Rosenthal DI, Doppelt SH, Potts Jr JT, Daly MA, Campbell JA, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986;1:377-81.
123. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-76.
124. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
125. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-6.
126. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-39.
127. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-55.
128. Finkelstein JS et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216-26.
129. Walker MD, Cusano NE, Sliney J Jr, Romano M, Zhang C, McMahon DJ, Bilezikian JP. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. 2013;44:237-46.
130. Bilezikian JP, Rubin MR. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep. 2006;4:5-13.
131. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
132. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
133. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung. 2010;60(5):267-72.
134. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013;98:592-601.
135. Recommendation to restrict the use of Protelos/Osseor (strontium ranelate). EMA/258269/2013;25 April 2013. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Press-release/2013/04/WC500142507.pdf. Accessed June 2013